The presentation was sponsored in part by an unrestricted educational grant from Shire Pharmaceuticals. Dr. Kollins reported having served as a member of McNeil's speakers bureau within the past three years as well as receiving grants or research support from Shire, Pfizer, Lilly, Psychogenics, Athenagen, and NRP. He also has served as a consultant for and receives honoraria from Shire, Cephalon, Lilly, Athenagen and Abbott.

Primary source: U.S. Psychiatric and Mental Health Congress regional extension
Source reference: Kollins SH, et al "New and Emerging Therapies in ADHD and Comorbid Substance Abuse Disorder" USPSYCH regional extension 2007.

Pages: 1  2  3  4